According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Realpage Inc., Anadigics Inc., Emergent BioSolutions Inc. and ScanSource.
Realpage Inc. (RP): Chairman, President and CEO Stephen T. Winn sold 80,000 shares
Winn sold 80,000 shares on Dec. 29 at an average price of $22.53. Realpage, along with its subsidiaries, is a provider of on demand software solutions for the rental housing industry. Realpage has a market cap of $1.76 billion; its shares were traded at around $22.45 with and P/S ratio of 3.82.
-
Warning! GuruFocus has detected 2 Warning Sign with KMT. Click here to check it out.
-
The intrinsic value of RP
Realpage Inc. announced its 2015 third quarter financial results. The company reported net sales of $121.6 million and GAAP net loss of $8.2 million.
Winn sold 442,682 shares of RP stock in November and December. EVP, CFO and Treasurer W Bryan Hill sold 69,000 shares of RP stock in November and December. EVP of Enterprise Solutions William P Chaney sold 31,521 shares of RP stock in December.
Anadigics Inc. (ANAD): Chairman and CEO Ronald Michels sold 67,707 shares
Michels sold 67,707 shares on Dec. 30 at an average price of $0.54. Anadigics was incorporated in the state of Delaware in 1984. Anadigics has a market cap of $56.630 million; its shares were traded at around 64 cents with and P/S ratio of 0.83.
Anadigics Inc. recognized net sales of $12.1 million and GAAP net loss of $6.2 million in its 2015 third quarter financial report.
Senior Vice President Jerry Lee Miller, COO Saders John Van, and SVP Infrastructure Products Timothy M Laverick Sr. sold 89,198 shares of ANAD stock altogether in December.
Emergent BioSolutions Inc. (EBS): President and CEO Daniel Abdun-nabi sold 63,209 shares
Abdun-nabi sold 63,209 shares on Dec. 24 at an average price of $39.06. Emergent BioSolutions was incorporated as BioPort Corporation under the laws of Michigan in May 1998 and subsequently reorganized as a Delaware corporation in June 2004. Emergent Biosolutions has a market cap of $1.56 billion; its shares were traded at around $40.01 with a P/E ratio of 41.10 and P/S ratio of 4.03. Emergent Biosolutions had an annual average earnings growth of 4.40% over the past 10 years. GuruFocus rated Emergent Biosolutions the business predictability rank of 2-star.
Emergent BioSoluations Inc. declared its 2015 third quarter financial results with revenues of $164.9 million and net earnings of $36.9 million.
Chairman and 10% owner Fuad El-hibri and EVP Barry Labinger together sold 83,611 shares of EBS stock in November.